NCT06334783终止1 期
Tumor Infiltrating Lymphocyte (TIL) Therapy for the Treatment of Advanced Solid Tumors
适应症
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 5
- 试验地点
- 3
- 主要终点
- Safety of TIL
研究概览
简要总结
Background:
Tumor-infiltrating lymphocyte (TIL) therapy is a type of adoptive cellular therapy by harvesting infiltrated lymphocytes from tumors, culturing and amplifying them in vitro and then infusing back to patients.
TIL therapy has shown strong efficacy for the treatment of solid tumors and has achieved high objective response rates in multiple cancers, such as melanoma, NSCLC, and cervical cancer.
Objective:
To evaluate the safety and efficacy of TIL for the patients with advanced solid tumor.
Eligibility:
Adults aging 18-75 with advanced solid tumor.
Design:
- Patients will undergo screening tests, including imaging procedures, heart and lung tests, and lab tests.
- Freshly resected patient tumors were dissected by the surgeon.
- TIL cells were isolated from the patient's tumor tissue, then cultured in vitro, activated and expanded.
- At last TIL cells will be re-infused into the patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Be able to understand and sign the Informed of Consent Document. Be willing to follow the procedure and protocol of the clinical trial.
- •Age ≥ 18 years and ≤ 75 years.
- •Expected survival time > 3 months.
- •ECOG score 0-
- •At least one lesion that could undergo surgery or biopsy to obtain tumor tissue for TIL preparation.
- •At least 1 measurable lesion (according to RECIST v1.1).
- •Metastatic or recurrent solid tumor, confirmed by histopathology. Patients who have failed previous standard treatment or currently do not have standard treatment, or who have been determined by the researcher to be unsuitable for current standard treatment due to other reasons.
- •Any previous anti-tumor treatment must exceed 28 days when collecting tumor tissue; The tumor tissue used for collecting and preparing TIL should not have undergone local treatment.
- •The bone marrow function of the subject's meets the following requirements:
- •Absolute neutrophil count (ANC) ≥ 1.5× 10e9/L.
- •Platelet (PLT） ≥ 75× 10e9/L.
- •Hemoglobin (HGB) ≥ 90 g/L.
- •Liver and kidney function:
- •Serum creatinine (Cr) ≤ 1.5 times of upper limit of normal (ULN) or creatine clearance ≥ 60 ml/min.
- •Serum Alanine aminotransferase (ALT) or/and Aspartate aminotransferase (AST) ≤ 2.5 times of ULN.
- •Total bilirubin (TBIL) ≤ 1.5 times of ULN.
- •Blood coagulation function:
- •Prothrombin time (PT) ≤ 1.5 ULN.
- •International Normalized Ratio (INR) ≤ 1.5 ULN.
- •or Activated Partial Thromboplastin Time (APTT) ≤ 1.5 ULN.
- •Left Ventricular Ejection Fractions (LVEF）≥45%.
- •Forced Expiratory Volume in the first second (FEV1）≥50%.
- •Women or men of childbearing potential should be ascetic or take contraception since the signing of ICF to 24 weeks or later after the last administration of drug.
排除标准
- •Female subjects who are in pregnancy or lactation or have a positive baseline blood pregnancy test.
- •Individuals who have experienced severe allergic reactions to any drug or its components in this trial in the past.
- •Received any investigational medication within 28 days prior to TIL cell transfusion or participated in another clinical study at the same time.
- •History of other known malignant tumors within the previous 5 years.
- •Primary central nerve system (CNS) cancer, or Participants with CNS metastasis after localized treatment.
- •History or syndrome of autoimmune diseases.
- •History of immunodeficiency, including testing positive for Human Immunodeficiency Virus (HIV), or having other acquired or congenital immunodeficiency diseases.
- •Have a history of ≥ grade 3 thromboembolic events within the past 6 months or are currently receiving thrombolytic or anticoagulant treatment due to high risk of thrombosis.
- •History of hereditary or acquired hemorrhagic diseases.
- •Clinical cardiovascular diseases or symptoms.
- •Active infection present.
- •Active pulmonary tuberculosis infection.
- •positive hepatitis B surface antigen or positive hepatitis B core antibody or positive hepatitis C virus antibody.
- •Syphilis spirochete antibody positive.
- •Patients received major surgery or under severe injury within 28 days before TIL infusion.
- •Patients who received live vaccine or attenuated live vaccine 28 days before TIL infusion.
- •Patients who have drug addiction history, alcoholism, or drug users.
- •Patients who have previously received cell therapy (such as TCR-T, CAR-T, TIL, etc.)
- •Patients not suitable for the clinical trial evaluated by the investigators.
结局指标
主要结局
Safety of TIL
时间窗: Day 0 - Day 730
The safety of TIL will be assessed based on the totality of dose-limiting toxicity (DLT) and adverse event (AE) data collected during this phase.
次要结局
- Overall Response Rate (ORR)(Day 0 - Day 730)
- Progression free survival (PFS)(Day 0 - Day 730)
- Overall survival (OS)(Day 0 - Day 730)
- Duration of Response (DOR)(Day 0 - Day 730)
- Disease Control Rate (DCR)(Day 0 - Day 730)
研究者
研究点 (3)
Loading locations...
相似试验
招募中
早期 1 期
A Study of TIL in Advanced Solid Tumors (DFGD)Advanced Solid TumorTumor Infiltrating LymphocytesTreatment Side EffectsEffects of ImmunotherapyNCT06488950Shanghai Juncell Therapeutics30
招募中
1 期
A Clinical Study on TIL for the Treatment of Advanced Solid TumorsAdvanced Solid TumorTumor Infiltrating LymphocytesTreatment Side EffectsEffects of ImmunotherapyNCT05087745Shanghai Juncell Therapeutics50
终止
1 期
HV-101 for Patients With Advanced Solid TumorsAdvanced Solid TumorsNCT05868915Hervor Therapeutics1
进行中（未招募）
1 期
ACT-TIL and ANV419 for Advanced Melanoma.Advanced MelanomaNCT05869539University Hospital, Basel, Switzerland10
招募中
1 期
A Study of GC101 TIL in Advanced Solid Tumors (TR)Advanced Solid TumorsNCT04967833Shanghai Juncell Therapeutics20